Tove Wästerlid

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Jag är specialistläkare i Hematologi vid Karolinska Universitetssjukhuset samt post-doc i gruppen för cancer epidemiologi på KEP. Jag forskar både
epidemiologiskt och molekylärbiologiskt om lymfom. För mer information om min forskning, publikationer och undervisning se den engelska versionen av den här sidan.

Artiklar

Article: HEALTH INFORMATICS JOURNAL. 2024;30(4):14604582241290725
Smart variant filtering - A blueprint solution for massively parallel sequencing-based variant analysis
Brahimllari O; Eloranta S; Georgii-Hemming P; Haider Z; Koch S; Krstic A; Skarp FP; Rosenquist R; Smedby KE; Taylan F; Thorvaldsdottir B; Wirta V; Wasterlid T; Boman M
Journal article: ECLINICALMEDICINE. 2024;74:102753
Clonal hematopoiesis of indeterminate potential and the risk of pulmonary embolism: an observational study
Liu Q; Smedby KE; Xue H; Waesterlid T; Li J; Fang F; Liu X
Article: ACTA ONCOLOGICA. 2024;63:563-572
The National Swedish Lymphoma Register - a systematic validation of data quality
Smedby KE; Eloranta S; Wasterlid T; Falini V; Jerlstrom U; Ellin F; Papworth K; Westerberg J; Lewerin C; Andersson P-O; Kristjansdottir HL; Brandefors L; Morth C-L; Hallen K; Kuric N; Abu Sabaa A; Wahlin BE; Molin D; Enblad G; Horsted A-S; Jerkeman M; Glimelius I
Article: EJHAEM. 2024;5(3):516-526
Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population-based study
Wasterlid T; Dietrich CE; Oksanen A; Spangberg LD; Wahlin BE; Enblad G; Andersson P-O; Kimby E; Smedby KE
Article: CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 2024;46:100785
Stable use of radiotherapy in lymphoma patients over time - A comprehensive national overview of radiotherapy use in Sweden with focus on older patients
Glimelius I; Ekberg S; Smedby KE; Wasterlid T
Article: ACTA ONCOLOGICA. 2024;63:164-168
Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival - a Swedish Lymphoma Register Study
Ekberg S; Molin D; Pahnke S; Bergstroem F; Branvall E; Smedby KE; Waesterlid T
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2024;204(3):967-975
Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study
Baech J; Husby S; Trab T; Kragholm K; Brown P; Gorlov JS; Jorgensen JM; Gudbrandsdottir S; Severinsen MT; Gronbaek K; Larsen TS; Wasterlid T; Eloranta S; Smeland KB; Jakobsen LH; El-Galaly TC
Article: HEMASPHERE. 2023;7(3):e838
Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden
Weibull CE; Wasterlid T; Wahlin BE; Andersson P-O; Ekberg S; Lockmer S; Enblad G; Crowther MJ; Kimby E; Smedby KE
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2023;98(1):23-30
Sex differences in lymphoma incidence and mortality by subtype: A population-based study
Radkiewicz C; Bruchfeld JB; Weibull CE; Jeppesen ML; Frederiksen H; Lambe M; Jakobsen L; El-Galaly TC; Smedby KE; Wasterlid T
Article: FRONTIERS IN ONCOLOGY. 2023;13:1176698
Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study
Haider Z; Wasterlid T; Spangberg LD; Rabbani L; Jylha C; Thorvaldsdottir B; Skaftason A; Awier HN; Krstic A; Gellerbring A; Lyander A; Hagglund M; Jeggari A; Rassidakis G; Sonnevi K; Sander B; Rosenquist R; Tham E; Smedby KE
Article: BRITISH JOURNAL OF CANCER. 2022;127(10):1808-1815
Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data
Syriopoulou E; Wasterlid T; Lambert PC; Andersson TM-L
Journal article: ANNALS OF LYMPHOMA. 2022;0(0):0
Diffuse large B-cell lymphoma among the elderly: a narrative review of current knowledge and future perspectives
Wästerlid T; Murphy S; Villa D; El-Galaly TC
Article: BLOOD ADVANCES. 2022;6(8):2657-2666
Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study
Joelsson J; Wasterlid T; Rosenquist R; Jakobsen LH; El-Galaly TC; Smedby KE; Eloranta S
Article: FRONTIERS IN ONCOLOGY. 2022;12:984021
Data-driven support to decision-making in molecular tumour boards for lymphoma: A design science approach
Ruiz NR; Abd Own S; Smedby KE; Eloranta S; Koch S; Wasterlid T; Krstic A; Boman M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;195(4):552-560
Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era
Branvall E; Ekberg S; Eloranta S; Wasterlid T; Birmann BM; Smedby KE
Article: EJHAEM. 2021;2(4):774-784
Excellent survival after R-Hyper-CVAD in hospitalized patients with high-risk large B-cell lymphoma: The Karolinska experience
Sonnevi K; Ljungqvist M; Joelsson JK; Harrysson S; Wasterlid T; Bernell P; Wahlin BE
Article: EJHAEM. 2021;2(3):525-529
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia
Lundin J; Mulder TA; Kattstrom M; Wasterlid T; Uddevik A; Mellstedt H; Heimersson K; Hansson L; Palma M; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):551-559
Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study
Wasterlid T; Oren Gradel K; Eloranta S; Glimelius I; El-Galaly TC; Frederiksen H; Smedby KE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(1):75-81
Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study
Sonnevi K; Wasterlid T; Melen CM; Harrysson S; Smedby KE; Wahlin BE
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2020;95(7):740-748
Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma
Wasterlid T; Harrysson S; Andersson TM-L; Ekberg S; Enblad G; Andersson P-O; Jerkeman M; Eloranta S; Smedby KE
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2020;95(6):652-661
Statin use is associated with improved survival in multiple myeloma: A Swedish population-based study of 4315 patients
Branvall E; Ekberg S; Eloranta S; Wasterlid T; Birmann BM; Smedby KE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(4):661-671
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Jakobsen LH; Ellin F; Smeland KB; Wasterlid T; Christensen JH; Jorgensen JM; Josefsson PL; Ovlisen AK; Holte H; Blaker YN; Grauslund JH; Bjorn J; Molin D; Lagerlof I; Smedby KE; Colvin K; Thanarajasingam G; Maurer MJ; Habermann TM; Song KW; Zhu KY; Gerrie AS; Cheah CY; El-Galaly TC
Journal article: BLOOD. 2019;134:4113
Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients
Ellin F; Smeland KB; Wasterlid T; Christensen JH; Jorgensen J; Josefsson PL; Holte H; Blaker YN; Grauslund JH; Bjoern J; Molin D; Lagerlof I; Smedby KEE; Colvin K; Thanarajasingam G; Maurer MJ; Habermann TM; Song K; Zhu KY; Gerrie AS; Cheah CY; El-Galaly TCC; Jakobsen LH
Article: JOURNAL OF INTERNAL MEDICINE. 2019;285(4):455-468
Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study
Wasterlid T; Mohammadi M; Smedby KE; Glimelius I; Jerkeman M; Bottai M; Eloranta S
Journal article: BLOOD. 2018;132:452
Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients
Jakobsen LH; Ellin F; Smeland KB; Wasterlid T; Christensen JH; Jorgensen J; Josefsson PL; Holte HJ; Blaker YN; Grauslund JH; Bjorn J; Molin D; Lagerlof I; Smedby KE; Colvin K; Thanarajasingam G; Gerrie AS; Cheah CY; El-Galaly TC
Article: HEMATOLOGICAL ONCOLOGY. 2017;35(2):151-157
Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study
Wasterlid T; Hartman L; Szekely E; Jerkeman M
Journal article: BLOOD. 2015;126(23):5039
Frequency and Clinical Implication of SOX11 Expression in Burkitt Lymphoma
Wasterlid T; Nordstrom L; Pedersen M; Norgaard PH; Gang AO; Brown PDN; Jerkeman M; Ek S
Journal article: BLOOD. 2014;124(21):4427
R-CHOEP-14 Is Associated with Superior Overall Survival Compared to R-CHOP-21 and R-CHOP-14 in Patients with DLBCL ≤ 70 Years - a Swedish Lymphoma Registry Population Based Study
Wasterlid T; Szekely E; Hartman LW; Jerkeman M
Article: ANNALS OF ONCOLOGY. 2013;24(7):1879-1886
Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group
Wasterlid T; Brown PN; Hagberg O; Hagberg H; Pedersen LM; D'Amore F; Jerkeman M
Article: LEUKEMIA AND LYMPHOMA. 2011;52(11):2090-2096
Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study
Wasterlid T; Jonsson B; Hagberg H; Jerkeman M
Visa fler

Alla övriga publikationer

Letter: ACTA ONCOLOGICA. 2023;62(6):560-564
The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results
Smedby KE; Waesterlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Osterborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Conference publication: BLOOD. 2022;140:3620-3621
Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study
Wasterlid T; Warnqvist A; Weibull CE; Wahlin BE; Andersson P-O; Enblad G; Kimby E; Smedby KE
Review: JOURNAL OF INTERNAL MEDICINE. 2022;292(2):243-261
Application of precision medicine in clinical routine in haematology-Challenges and opportunities
Wasterlid T; Cavelier L; Haferlach C; Konopleva M; Froehling S; Ostling P; Bullinger L; Fioretos T; Smedby KE
Preprint: RESEARCH SQUARE. 2022
Survival by first-line treatment type and timing of progression among follicular lymphoma patients: A national population-based study in Sweden
Weibull C; Wästerlid T; Wahlin B; Andersson P-OA; Ekberg S; Lockmer S; Enblad G; Crowther M; Kimby E; Smedby KE
Conference publication: BLOOD. 2021;138:4587
Good Outcome after R-Hyper-CVAD/R-MA in High-Risk Aggressive B-Cell Lymphoma: A Single-Center Experience
Sonnevi K; Ljungqvist M; Joelsson JK; Harrysson S; Wasterlid T; Bernell P; Wahlin B
Meeting abstract: BLOOD. 2021;138:2534
Sex Differences in Lymphoma Incidence and Excess Mortality By Subtype: A Comprehensive National Study
Radkiewicz C; Bruchfeld JB; Weibull C; Lambe M; Jakobsen LH; El-Galaly TC; Smedby KE; Wästerlid T
Letter: BLOOD CANCER JOURNAL. 2021;11(5):100
Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study
Wasterlid T; Hasselblom S; Joelsson J; Weibull CE; Rassidakis G; Sander B; Smedby KE
Meeting abstract: BLOOD. 2019;134:1618
Encouraging Outcomes with Intensive Chemotherapy for Patients with Primary Mediastinal B-Cell Lymphoma - a Swedish Lymphoma Register Study
Wasterlid T; Rassidakis GZ; Sander B; Smedby KE
Conference publication: BLOOD. 2018;132:571
Clinical Characteristics and Outcomes Among Very Elderly Patients with Major Lymphoma Subtypes: A Nordic Lymphoma Group Study
Wasterlid T; Gradel K; Jerkeman M; Frederiksen H; Smedby KE
Letter: ANNALS OF ONCOLOGY. 2018;29(8):1882-1883
Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study
Wasterlid T; Biccler JL; Brown PN; Bogsted M; Enblad G; Jorgensen JM; Christensen JH; Wahlin BE; Smedby KE; El-Galaly TC; Jerkeman M
Letter: LEUKEMIA AND LYMPHOMA. 2017;58(7):1760-1763
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
Wasterlid T; Nordstrom L; Freiburghaus C; Pedersen M; Norgaard P; Gang AO; Brown P; Dictor M; Jerkeman M; Ek S
Conference publication: BLOOD. 2017;130
Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B Cell Lymphoma - a Nordic Lymphoma Group Population Based Study
Wasterlid T; Biccler JL; Brown PDN; Christensen JH; Enblad G; Jorgensen JM; Smedby KE; El-Galaly TC; Jerkeman M
Conference publication: HAEMATOLOGICA. 2016;101:403
FREQUENCY AND CLINICAL IMPLICATIONS OF SOX11 EXPRESSION IN BURKITT LYMPHOMA
Wasterlid T; Nordstrom L; Pedersen M; Norgaard P; Gang AO; Brown P; Jerkeman M; Ek S
Conference publication: ANNALS OF ONCOLOGY. 2011;22:190-191
PROPOSAL OF A MODIFIED PROGNOSTIC INDEX FOR ADULT BURKITT LYMPHOMA - A POPULATION BASED SWEDISH LYMPHOMA REGISTRY STUDY
Wasterlid T; Jonsson B; Hagberg H; Jerkeman M

Forskningsbidrag

Epidemiologiska och genetiska studier av lymfom hos äldre för framtida precision i diagnostik och behandling
ALF Region Stockholm (Kliniska postdoktorer)
1 January 2020 - 1 January 2023
Genetic studies and evaluation of cell-free tumour DNA for future diagnostic and therapeutic precision in lymphoma
Åke Olssons stiftelse
Magnus Bergvall Foundation
Genetic studies and evaluation of cell-free tumour DNA for future diagnostic and therapeutic precision in lymphoma
Svenska Läkaresällskapet (SLS Projektanslag) (971438)
Genetic studies and evaluation of cell-free tumour DNA for future diagnostic and therapeutic precision in lymphoma
Jeanssons Stiftelse
Epidemiological studies on elderly patients with lymphoma
Karolinska Institutet Stiftelser och Fonder
Epidemiological and genetic studies on lymphoma for future diagnostic and therapeutic precision
Åke Wibergs Stiftelse
Könsrelaterade skillnader i incidens och överlevnad vid lymfom
Gunnar Grimfors gåvofond
Könsrelaterade skillnader i incidens och överlevnad vid lymfom
Karolinskas fond för leukemiforskning

Anställningar

Anknuten till Forskning, Medicin, Solna, Karolinska Institutet, 2017-2026
ST-läkare Hematologi, Department of Hematology, Karolinska University Hospital, 2017-2023

Handledare

Erik Boberg, 2023
Linn Deleskog Spångberg, 2022
Johanna Borg Bruchfeld, Sex-related differences in incidence and outcomes among patients with lymphoma: epidemiological and biological perspectives, https://ki.se/en/people/johanna-borg-bruchfeld, 2021
Joel Joelsson, 2019

Om mig

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Handledare

Nyheter från KI

Kalenderhändelser från KI